Work

Evaluation of non-classical response by immune-modified RECIST and efficacy of atezolizumab beyond disease progression in advanced NSCLC: Results from the randomized Phase II study POPLAR

Year: 2017

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdx091.016

Authors: A. Artal-Cortes, J. Mazieres, L. Fehrenbacher, A. Rittmeyer, A.I. Spira, K. Park, C. Lewanski, S. Liu, M. Ballinger, J. Vansteenkiste

Institutions: Hospital Universitario Miguel Servet, Centre Hospitalier Universitaire de Toulouse, Kaiser Permanente Vallejo Medical Center, Virginia Cancer Specialists, Samsung Medical Center, Sungkyunkwan University, Charing Cross Hospital, Genentech, KU Leuven

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2612737548

FWCI: 0.482

Cites:

Cited by: 7

Related to: 10